


# VACC-ZERA

## Nucleic Acid Vaccine Platform



## Improving Nucleic Acid vaccines

# VACC-ZERA

allows the

# SLOW RELEASE

of antigens sustaining the immune response in the long term



### Business Model

- Technology evaluation agreement
- Joint development agreement
- R&D license
- Commercial license



### Intellectual property

- VACC-ZERA technology
- Fully owned and patented (WO2010/040847)



### Universal

- Nucleic Acid Vaccine Platform
- Complex antigens of any size



### Fast and simple

- Fast design and development



### Validated method

- In vivo POC, Full Data-Pack available
- Prostate cancer: Full tumor regression
- HPV (E7), LCMV (NP): Virus clearance




### Additional features

- Improved biological performance of nucleic acid vaccines
- Strong Cellular and Humoral responses
- Depot effect: high antigen levels
- High stability
- Adjuvant effect: Increased cellular response
- Antigen display system: Enhanced processing by APCs

# VACC-ZERA

## Nucleic Acid Vaccine Platform


### Prostate cancer - Preclinical



Tumor regression trial in mice  
Zera®-PCA1302 DNA

Full Tumor  
Regression

### LCMV - Preclinical



Challenge trial in mice  
LCMV Zera®-NP DNA

Full Virus  
clearance